SAN FRANCISCO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company's Management will participate in the following upcoming investor conferences in August:
- BTIG Virtual Biotechnology Conference 2021
Format: Fireside chat and one-on-one investor meetings
Date: Monday, August 9, 2021
Presentation Time: 3:30 p.m. EDT
- Canaccord Genuity 41st Annual Growth Conference
Format: One-on-one investor meetings
Date: Wednesday, August 11, 2021
BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
